QVM149
Sponsors
Novartis Pharma AG, Novartis Pharmaceuticals, Dr. Grace Parraga, University Medical Center Groningen
Conditions
Allergic AsthmaAsthma
Phase 3
A Long-term Safety Study of QVM149 in Japanese Patients With Asthma
CompletedNCT03100825
Start: 2017-04-28End: 2019-04-08Updated: 2020-04-07
Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium
CompletedNCT03158311
Start: 2018-02-05End: 2019-07-19Updated: 2021-10-08
Investigating the Effects of QVM149 on MRI Ventilation Defects
WithdrawnNCT04206761
Start: 2021-12-01End: 2022-12-01Updated: 2021-12-14
Anti-inflammatory Effects Glycopyrronium
CompletedNCT04259164
Start: 2020-09-10End: 2022-12-29Updated: 2023-01-12
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
Not yet recruitingNCT05776927
Start: 2026-05-29End: 2029-12-24Target: 304Updated: 2026-02-03
A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.
Not yet recruitingCTIS2022-502365-26-00
Target: 22Updated: 2026-06-02